INTRODUCTION
Clostridium difficile infection (CDI) is the most common cause of nosocomial diarrhea in adults [1, 2] . The clinical manifestations of CDI range from mild diarrhea to fulminant colitis and severe sepsis, which may be life threatening [2, 3] . Metronidazole and vancomycin have been mainstays in CDI treatment guidelines for several decades, but increasing rates of refractory disease have necessitated the consideration of alternative therapies [1, 4] .
According to a recent United States Centers for
Disease Control and Prevention (CDC) report, C. difficile is one of only three pathogens to be classified as an ''urgent'' threat to public health due to increasing rates of antimicrobial resistance [5] . Moreover, the emergence of the hypervirulent NAP1/BI/PCR ribotype 027 strain has been associated with severe, recurrent disease that is often non-responsive to standard therapy [6] .
Metronidazole and vancomycin are still recommended for the initial management of CDI; however, there are no consensus guidelines for the treatment of CDI that is refractory to these agents [1] . Tigecycline is a broad spectrum glycylcycline antibiotic that is approved for use in the United States for the treatment of complicated skin and soft tissue infections, intra-abdominal infections, and community-acquired pneumonia [7] . Multiple studies have demonstrated the favorable in vitro activity of tigecycline against C.
difficile isolates [8] [9] [10] . Additionally, tigecycline has demonstrated a low minimum inhibitory concentration (MIC) among multidrug-resistant C. difficile isolates (mean MIC 90 0.25 mg/L; range B0.06-2 mg/L) relative to its achieved fecal concentrations at standard doses (mean concentration 6.0 mg/kg; range 3.0-14.1 mg/ kg) [8, 10, 11] . Tigecycline is excreted into the gastrointestinal tract with limited disruption of intestinal flora, making it an ideal candidate for the treatment of CDI [9, 12, 13] .
Despite the favorable in vitro activity profile of tigecycline against C. difficile, there is limited clinical data describing its use in the management of CDI. There are limited case reports of the use of tigecycline for the treatment of CDI described in the literature [14] [15] [16] [17] . Therefore, the objective of this study was to detail our experience using tigecycline for the treatment of CDI.
METHODS

Patients
This was a retrospective case series of hospitalized patients at the University of Kansas Hospital, a tertiary care academic medical center. All adult patients who were treated with tigecycline for CDI from January [18] . Additionally, an ATLAS score was computed for each patient as described by Miller et al. [19] . ATLAS is a validated scoring system used to predict response to antibiotic treatment against CDI [19] . In general, the higher the ATLAS score, the lower the observed clinical cure rate [19] . To estimate individual comorbidity burden, the Charlson comorbidity index (CCI) was computed for each patient [20] .
Outcome Measures
The primary outcome of this study was clinical cure, defined by the resolution of the following signs and symptoms of CDI maintained for the subsequent duration of tigecycline therapy without further addition of an anti-CDI agent: 
RESULTS
A total of 251 hospitalized patients who received tigecycline between January 2007 and July 2013 at our institution were screened for inclusion in this study. Of these patients, nine were treated with tigecycline for CDI. Two patients were excluded due to\48 h of treatment with tigecycline. In both of these cases, alternative agents for CDI were used according to the decision of a treating physician. A total of seven patients met study criteria and were included in the final analysis.
Case Reports
Case 1 occurred in a 64-year-old female who was admitted for community onset CDI. This . This patient had a number of risk factors for CDI, including admission from a long-term care facility and multiple prior antibiotic use (see Table 1 for full listing). He was treated initially with oral metronidazole 500 mg three times daily. Oral metronidazole was switched to intravenous and oral vancomycin 125 mg four times daily was added on hospital day 2 upon detection of toxigenic C. difficile. At this point, the patient was intubated due to decreasing respiratory function and pulmonary edema. He also had other symptoms of severe complicated CDI, included nausea and vomiting, abdominal pain, colonic wall thickening, and ascites. Oral vancomycin was changed to rectal vancomycin 500 mg four times daily on hospital day 3 due to the development of paralytic ileus. This regimen continued through hospital day 7, with fever, ileus, and abdominal pain resolving. On hospital day 8, the patient again developed diarrhea with abdominal pain and persisting leukocytosis (WBC 24,300/lL). Due to these non-resolving symptoms and the severity of the patient's condition, intravenous tigecycline was added on hospital day 8 as a Tigecycline was added on hospital day 27 for dual coverage of enterococcal pancreatitis and C. difficile. Oral vancomycin 250 mg four times daily was also added at this time and metronidazole was discontinued by decision of the treating physician. Fever and leukocytosis subsided and diarrhea improved on 8 days of combination therapy with tigecycline and oral vancomycin. There was no recurrence of CDI on record.
Case 4 occurred in an 80-year-old female who was admitted due to increasing fatigue and copious diarrhea consistent with community onset CDI. Her risk factors for CDI included advanced age and recent antibiotic use (vancomycin, levofloxacin, and piperacillintazobactam). This patient's initial severity of illness was mild (WBC 9,100/lL, serum creatinine 116% of the premorbid level) and she was treated with oral metronidazole 500 mg three times daily beginning on hospital day 1. After 3 days of metronidazole treatment, her abdominal pain had improved, but the diarrhea persisted and her WBC began trending upward (16,500/lL). On hospital day 4, the patient developed septic shock secondary to CDI. As her CDI had progressed to a severe complicated case, intravenous tigecycline and vancomycin 250 mg four times daily were added. Tigecycline was given as a 100-mg loading dose followed by 50 mg twice daily. The patient was treated successfully with 6 days of triple therapy with tigecycline, vancomycin, and metronidazole. Due to the high risk of CDI recurrence in this patient, a vancomycin taper was completed.
The patient was discharged to home and had no CDI recurrence within 28 days of follow-up.
Case 5 occurred in a 68-year-old male who was admitted to the hospital for febrile neutropenia secondary to pre-B cell acute lymphoblastic leukemia. This patient had multiple risk factors for CDI, including advanced age, hematologic malignancy, multiple prior antibiotic use (trimethoprimsulfamethoxazole, levofloxacin, linezolid, and cefepime), prior chemotherapy use, and hospitalization. On hospital day 6, the patient developed acute respiratory distress and severe sepsis (4/4 SIRS criteria). On hospital day 7, the patient developed diarrhea and C. difficile toxin was detected. This case was classified as severe complicated CDI and treated initially with two days of intravenous metronidazole 500 mg three times daily and oral vancomycin 125 mg four times daily. On hospital day 9, tigecycline was added due to persisting diarrhea ([800 mL liquid stool) and fever (38.2°C). The patient's fever resolved on hospital day 11, diarrhea resolved on hospital day 14, and clinical cure was achieved. Triple therapy with tigecycline, vancomycin, and metronidazole was continued for a total of 21 days due to concerns for recurrence in the context of the patient's pancytopenia. At this time, the patient was switched to palliative care due to underlying cancer with a poor overall prognosis. He tolerated treatment with tigecycline well and no side effects were reported. The patient was discharged home to hospice with no further CDI treatment. Sustained response was unevaluable due to death within 28 days of tigecycline completion. 
DISCUSSION
In this case series, we describe the successful use of tigecycline combination therapy for the treatment of severe and severe complicated CDI. A summary of patient characteristics, selected risk factors, antimicrobial treatments, and clinical outcomes is presented in Table 1 . The majority of patients [85.7% (n = 6/7)] were classified as having severe complicated CDI upon initiation of tigecycline therapy. In all of the included cases, tigecycline was administered intravenously as a 100-mg loading dose, followed by 50 mg twice daily for the times per day is preferred for the treatment of severe CDI [1] . Unfortunately, in cases of severe complicated CDI where gut motility is impaired, the efficacy of oral vancomycin is questionable [1] . In these instances, addition of rectal vancomycin or intravenous metronidazole is recommended, although the delivery of rectal vancomycin may be insufficient and adds the risk for colonic perforation [1] . There are currently no other alternatives to these agents in severe and severe complicated CDI mentioned in the current guidelines [1] . Recent evidence indicates fidaxomicin is non-inferior to vancomycin in the treatment of severe CDI [21] . None of the patients included in this study received fidaxomicin; however, only 2 of the 7 cases (case 5 and 6) occurred after the introduction of fidaxomicin to the market. At the time of these cases, data on the effectiveness of fidaxomicin in severe CDI had not been widely disseminated, which may explain why this agent was not used. Of note, fidaxomicin is only available in oral formulation, which prevents its use in cases where intravenous treatment is required.
Based on the data presented in this case series, combination therapy with tigecycline appears to be a reasonable alternative in the treatment of severe and severe complicated CDI, including cases that are unresponsive to standard therapy. While it is difficult to attribute the high clinical cure rate observed in these cases solely to the addition of tigecycline, all of the patients had unresolved symptoms and met criteria for severe or severe complicated CDI upon tigecycline initiation.
Several published case reports have also described the successful use of tigecycline for CDI, either as monotherapy or in combination with other agents [15] [16] [17] 22] . In contrast, there has been one published failure of tigecycline to treat severe CDI [23] . To our knowledge, there is no in vitro data on tigecycline combinations against C. difficile isolates, but tigecycline alone exhibits potent activity [8, 10] . Results from a recent study also suggest that tigecycline can The present investigation has a number of limitations. First, this was a retrospective of case series and is limited by the lack of a comparison group. In 2 of the patients (cases 3 and 4), vancomycin and tigecycline were initiated on the same day, making any potential added benefit from tigecycline difficult to determine.
In another case (case 7), tigecycline was added after only 1 day of treatment with metronidazole. Therefore, it is unclear if the infection would have resolved without the addition of tigecycline. Finally, C. difficile strain typing and susceptibility testing is not routinely performed at our institution and this potentially informative data were not available for any of the included cases.
Perhaps the greatest strength of this study was the ability to capture cases of severe and fulminant CDI, which are usually excluded from clinical trials and experimental studies. Observed 28-day mortality was only 28.6%
(n = 2/7), which we consider to be low relative to the severity of illness observed. Mortality in severe fulminant CDI is as high as 90% overall and 75% post-colectomy [1, 3] . The basis for the substantially lower mortality rate in the present study is unclear. Tigecycline is a derivative of minocycline, which has well-established antiinflammatory properties and has been shown to 
